1. Home
  2. FF vs LUNG Comparison

FF vs LUNG Comparison

Compare FF & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FutureFuel Corp.

FF

FutureFuel Corp.

N/A

Current Price

$5.40

Market Cap

212.3M

Sector

Industrials

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

N/A

Current Price

$2.06

Market Cap

97.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FF
LUNG
Founded
N/A
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Industrial Specialties
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
212.3M
97.1M
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
FF
LUNG
Price
$5.40
$2.06
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
507.7K
410.6K
Earning Date
05-11-2026
04-29-2026
Dividend Yield
5.32%
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$3.09
$1.13
52 Week High
$6.99
$2.89

Technical Indicators

Market Signals
Indicator
FF
LUNG
Relative Strength Index (RSI) 53.38 50.76
Support Level $5.06 $1.20
Resistance Level $6.99 $2.44
Average True Range (ATR) 0.21 0.14
MACD -0.04 -0.06
Stochastic Oscillator 50.74 17.31

Price Performance

Historical Comparison
FF
LUNG

About FF FutureFuel Corp.

FutureFuel Corp makes and sells diversified chemical products, bio-based fuel products, and specialty chemical products. The company is organized into two segments based on product type: biofuels and chemicals. The biofuels segment sells biodiesel and other petroleum products, with fuels made from a mix of diesel, vegetable oils, and grease feedstock. The chemicals segment, which generates the majority of revenue, sells products used in the production of agricultural chemicals, including herbicides, as well as coatings and cleaning products such as detergents.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: